Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss new insights into the mechanisms by which hepatitis B virus (HBV) and hepatitis C virus (HCV) may develop resistance to antiviral therapy
- Summarize recent findings related to cross-resistance between antiviral agents used in the treatment of patients with chronic HBV or HCV infection
- Describe the latest data on clinical strategies that may minimize the risk of selection of drug-resistant HBV or HCV
- Discuss new findings on approaches to the antiviral management of patients with drug-resistant HBV or HCV
Topics covered include:
- Hepatitis B: Meeting Summary
- Novel HBV Therapies
- Resistance Rates Associated With HBV Therapies
- Combination vs Monotherapy
- Monitoring for Resistance
- Management of Resistance
- Mechanisms of Action of Currently Approved Agents for HCV Infection
- Viral Dynamics in Nonresponse or Developing Resistance
- New HCV Therapies: Protease Inhibitors
- New HCV Therapies: Polymerase Inhibitors
- STAT C Agents in HCV Treatment Failure
- Future Treatment Strategies